Skip to main content
The Egyptian Heart Journal

Table 2 Baseline investigations and target organ damage

From: Effect of Amlodipine/Nebivolol combination therapy on central BP and PWV compared to Amlodipine/Valsartan combination therapy

 

A/V [n = 52 (%)]

A/N [n = 50 (%)]

P value

Investigations

 Lipid profile

  CH

179.7 ± 43.7

171.7 ± 43.7

0.355

  TG

145.3 ± 57.5

148.0 ± 57.2

0.808

  LDL

106.2 ± 39.1

104.3 ± 32.5

0.786

  HDL

49.6 ± 17.52

52.2 ± 22.0

0.505

 AL/Cr

49.7 ± 120.3

41.6 ± 116.3

0.729

 Fundus examination^

  G0

49 (94.2)

44 (88.0)

0.464

  G1

2 (3.8)

2 (4.0)

 

  G2

1 (1.9)

2 (4.0)

 

  G3

0 (0.0)

2 (4.0)

 

Echocardiographic data

 EF % (mean ± SD)

64.2 ± 5.9

64.1 ± 6.5

0.954

 IVS

1.0 ± 0.1

1.0 ± 0.1

0.712

 PWT

1.0 ± 0.4

1.1 ± 0.7

0.442

Target organ damage

 LVH

10 (19.2)

9 (18.0)

0.873

 Retinopathy

3 (5.8)

6 (12.0)

0.267

 Stroke

1 (1.9)

0 (0.0)

0.324

 Nephropathy

7 (13.5)

5 (10.0)

0.588

  1. A/V, Amlodipine/Valsartan; A/N, Amlodipine/Nebivolol; CH, total cholesterol; TG, triglycerides; LDL, low-density lipoprotein; HDL, high-density lipoprotein; AL/CR, albumin-to-creatinine ratio; EF, e ejection fraction; IVS, intraventricular septum; PWT, posterior wall thickness; LA, left atrium; DD, diastolic dysfunction; LVH, left ventricular hypertrophy
  2. *A p-value less than or equal 0.05 is statistically significant
  3. ^Fundus examination Grades; G0: No visible abnormalities, G1: Diffuse arteriolar narrowing, G2: G 1 + focal arteriolar constriction, G3:G2 + retinal hemorrhage
Back to article page